Mease PJ, Kellner H, Morita A, et al. Efficacy and Safety Results from a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor, in Patients with Active Psoriatic Arthritis. ACR 2017, abstract 2L.
Functie van endotheel bij RA
aug 2017 | RA
nov 2022 | Psoriasis
nov 2020
okt 2020
aug 2020 | RA, SLE